William joined Pappas Capital in 2023 as a Venture Partner. Prior to joining Pappas, he was the Founding Managing Director for Asia at Bryan Garnier & Co., a leading European boutique investment bank headquartered in Paris with over 180 bankers. In this role, he specialized in advising mid-cap, high-growth, and disruptive companies.

William has served for many years as an advisor to EPS Holdings, one of the largest privately held clinical CROs headquartered in Tokyo, Japan. He also holds an advisory position serving the Chairman of Hong Kong WinHealth Pharma Group, a prominent pharmaceutical company focused on commercialization of rare diseases and specialty pharmaceuticals in the Greater China region.

Before transitioning to the investment sector, William’s last corporate role was with Bayer Healthcare in the Far East as the Chief of Strategic Sourcing. He led a cross-category strategic sourcing and quality compliance team, managing a volatile supply chain with an annual spend of half a billion euros. Prior to joining Bayer in July 2012, William held various globally-based strategic sourcing and business development/sales marketing positions of increasing responsibility at Takeda (Singapore), Johnson & Johnson (California), and Pfizer (NYC and Madrid) on the buy side, and for PPD (then part of the Carlyle Group and now part of Thermo Fisher) and Quintiles Transnational (now rebranded as IQVIA) on the supply side. His career has spanned over 25 years across Singapore, the US, Europe, and China.

William is a member of the BayHelix Group, a non-profit professional organization of business leaders from the investment and health-tech communities. The group’s mission is to shape the growth of the life science industry, foster business collaborations, and share information and career experiences among its members. Educated in both China and the US, William is based in Wuxi near Shanghai. He is fluent in English and Mandarin Chinese.